Antibiotics are the foundation element in modern medicine and have a record of reducing the burden of infectious diseases, reduce and even contain mortality. Ability of prompt treatment of infections without the need for identifying the causative pathogen has resulted in curbing the prevalence of infections and opened several opportunities for modern medicine in form of surgeries, organ transplantation, chemotherapy and neonatal and pediatric care. However, all such benefits are eating away the mentioned and many more benefits, leading the WHO to warn on the possibility of post-antibiotic era, and the associated burden of antibiotic resistance. With continued antibiotic resistance, it is anticipated that by 2050, antibiotic resistant infections will account for more than 10 million annual deaths and the cost burden on the global economy to reach up to USD 100 trillion.
Management and containment of antibiotic resistance is a multi-faceted clinical, regulatory and economic approach. Such steps range from improving regulatory framework, pumping the pipeline, development of new narrow spectrum antibiotics and alternative therapies, changing therapy goals, to incentivizing targeted antibiotic development. A major aspect of antibacterial strategy is the development and commercialization of targeted antibiotics, i.e. antibacterial drugs that are specific to a species or genus. This study discusses the challenges and advantages to this approach and highlight some recommendations that will help move towards the identification of narrow spectrum and targeted antibiotics. This review is not a comprehensive compilation of reviews and market trends, but is to be used as a highlight of some recent advancements and prevalent dynamics in the area of targeted antibiotics.
The promising strategies for combating resistant bacterial infections can be prevention of infection and consequent risk of resistance, refurbishing of the antibiotic pipeline aby deploying a blend of economic and regulatory measures, slowing the risk of resistance by preserving the use of available antibiotics, developing a novel approach of microbe-attacking treatments to reduce the potential to resistant infections, developing species specific and narrow spectrum antibiotics, and developing treatments that host targets than the microbial agents.
Improved usage regimen to augment the utility of currently available antibiotics is indeed the best strategy to contain the risk of resistance, however, lack of well-defined tracking mechanism and availability of uniform resources holds back the potential of this approach. An alternative approach is the development of novel antibiotics as a targeted approach, thus attacking the causative pathogen, and therefore have a reduced or even minimal impact on the microbiota. Spectrum antibiotics are often viewed as a generalized and coarse approach these drugs not only tackle the causative pathogen but also cause a visible damage to the other microbiome. Thus such untargeted treatments can have critical consequences in terms of eventual disease development, and hence urges the need for novel generation of antibiotics, and eventual requirement for a shift to address these concerns. Some potential candidates that have recently reached late stage clinical development (targeted pathogen specific antibiotics) include Ridinilazole, Afabicin, and AR-101. There are some preclinical candidates that are potential treatments for resistant bacteria.
The visible collapse of the antibiotic R&D pipeline is opined to be a result of economic as well as regulatory challenges, that are further discussed in this report. The solution to overcome these challenges are recommended to be a better tuning and alignment of the regulatory and economic approaches to antibiotic development. Public private partnerships (PPP) can be a potential step to align R&D focus with the unmet needs.
Novel regulatory outlook and respective approach such as the Limited Population Antibiotic Drug initiative from the Infectious Disease Society of America can also enable drugs approval corresponding to small and inexpensive clinical trials focusing on select infections caused by highly resistant agents. Such initiatives are thus recommended to empower antibiotic ownership by clinicians and provide monetary incentives by reducing the cost of clinical trials. This report comprehensively discusses the current and future status of the overall broad and narrow spectrum antibiotics market. this study also gives a glimpse of the major strategies developed and deployed by governments, clinicians and pharmaceutical manufacturers in development of targeted antibiotics. The study is concluded with measures taken for reducing the risk of further antibiotic resistance and analytical recommendations in terms of economic, regulatory and clinical approaches that can be taken in this space.
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
This text is related
to segments covered.
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
This text is related
to country scope.
The List of Companies
- GlaxoSmithKline PLC
- Pfizer Inc.
- Johnson & Johnson Inc.
- Merck & Co. Inc.
- Bayer AG
- Novartis AG
- Sanofi SA
- F. Hoffmann La Roche AG
- Eli Lilly & Company
- Otsuka Pharmaceutical Co. Ltd.
- STADA Arzneimittel
- Cubist Pharmaceuticals
- Abbott Laboratories
- Shionogi & Co., Ltd.
- Daiichi Sankyo
- Astellas Pharma
- Sun Pharmaceutical Industries
- Top Antibiotic Startups
- Arixia Pharmaceuticals
- Acurx Pharmaceuticals
- Locus Biosciences
- Paratek Pharma
- Destiny Pharma
- Vedanta Biosciences
- Spero Therapeutics
- Oxford Drug Designs
- Entasis Therapeutics
- Melinta Therapeutics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)
Enteral and Parenteral Medical Nutrition Market
Forecast to 2028 - Global Analysis by Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer's Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole–Source), Form (Liquid, Powder, and Semi–Solid), Product Type (General and Disease–Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18–60 Years, 3–18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
CIN & HR-HPV Treatment Market
Forecast to 2028 - Global Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)
Pharmaceutical Fluid Handling Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Offering (Equipment & Solutions and Services), Tubing (Thermoplastic Elastomers, Polyvinyl Chloride, and Silicone), Application (Fluid Handling & Management, Fluid Preparation, Integration & Automation, Buffer Management, and Others), Usage (Cough Syrup, Intravenous Product, Complex Active Pharmaceutical Ingredients, and Others), and End User (Biotechnology Companies, Pharmaceutical & Medical Companies, and Others)
Enteral Medical Nutrition Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]
Glycomic Therapeutics Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]